PCM
ENZ

Prelude Capital Management’s Enzo Biochem, Inc. ENZ Stock Holding History

Prelude Capital Management’s Portfolio ENZ Stock Details ENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-45,500
Closed -$94K – 2009
2022
Q2 		$94K Hold
45,500
– – ﹤0.01% 1429
2022
Q1 		$132K Hold
45,500
– – ﹤0.01% 1355
2021
Q4 		$146K Hold
45,500
– – ﹤0.01% 1645
2021
Q3 		$161K Hold
45,500
– – ﹤0.01% 1416
2021
Q2 		$144K Sell
45,500
-4,500
-9% -$14.2K ﹤0.01% 1424
2021
Q1 		$172K Sell
50,000
-50,000
-50% -$156K ﹤0.01% 1356
2020
Q4 		$252K Hold
100,000
– – 0.01% 1001
2020
Q3 		$211K Buy
+100,000
New +$238K 0.01% 673
2018
Q2 		– Sell
-1,488
Closed -$8K – 1996
2018
Q1 		$8K Buy
+1,488
New +$10.5K ﹤0.01% 1382
2017
Q2 		– Sell
-28,800
Closed -$241K – 1907
2017
Q1 		$241K Buy
28,800
+8,700
+43% +$61.3K 0.02% 505
2016
Q4 		$139K Buy
20,100
+13,000
+183% +$83K 0.02% 713
2016
Q3 		$36K Sell
7,100
-6,100
-46% -$36.4K ﹤0.01% 1152
2016
Q2 		$79K Buy
13,200
+900
+7% +$5K 0.01% 844
2016
Q1 		$56K Sell
12,300
-2,200
-15% -$9.79K 0.01% 946
2015
Q4 		$65K Sell
14,500
-6,400
-31% -$27K 0.01% 971
2015
Q3 		$66K Hold
20,900
– – 0.01% 968
2015
Q2 		$63K Sell
20,900
-4,300
-17% -$12.1K 0.01% 1069
2015
Q1 		$74K Sell
25,200
-4,500
-15% -$14.7K 0.01% 1139
2014
Q4 		$132K Buy
29,700
+1,400
+5% +$6.68K 0.02% 901
2014
Q3 		$146K Buy
+28,300
New +$151K 0.02% 861

Other funds holding ENZ

HFA
Harbert Fund Advisors Birmingham, Alabama $3.03M AUM 40.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RAM
Roumell Asset Management Chevy Chase, Maryland $53.3M AUM 8.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCA
VIEX Capital Advisors Sunny Isles Beach, Florida $30.9M AUM 55.48% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
PCM
Potomac Capital Management New York $115M AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Prelude Capital Management's ENZ Position: Q3 2022 in Review

Prelude Capital Management sold out of Enzo Biochem, Inc. (ENZ) in Q3 2022, closing a stake of 45,500 shares — an estimated $94K sold.

Prelude Capital Management first reported a position in ENZ in Q3 2014 and held it in 20 quarters. The position peaked at $252K in Q4 2020. 49 funds tracked by Wall St. Rank hold ENZ as of Q3 2022.

  • Prelude Capital Management reported no remaining Enzo Biochem, Inc. position as of Q3 2022 after selling out during the quarter.
  • Prelude Capital Management sold 45,500 Enzo Biochem, Inc. shares in Q3 2022, an estimated $94K.
  • Prelude Capital Management first reported a position in Enzo Biochem, Inc. in Q3 2014 and held it in 20 quarters.
  • Prelude Capital Management's Enzo Biochem, Inc. position peaked at $252K in Q4 2020.
  • 49 funds tracked by Wall St. Rank held Enzo Biochem, Inc. as of Q3 2022.

Based on Prelude Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.